Details for New Drug Application (NDA): 006530
✉ Email this page to a colleague
NDA 006530 describes AVC, which is a drug marketed by Norvium Bioscience and is included in one NDA. Additional details are available on the AVC profile page.
The generic ingredient in AVC is sulfanilamide. There are six drug master file entries for this compound. Additional details are available on the sulfanilamide profile page.
The generic ingredient in AVC is sulfanilamide. There are six drug master file entries for this compound. Additional details are available on the sulfanilamide profile page.
Summary for 006530
| Tradename: | AVC |
| Applicant: | Norvium Bioscience |
| Ingredient: | sulfanilamide |
| Patents: | 0 |
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CREAM;VAGINAL | Strength | 15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Jan 27, 1987 | TE: | RLD: | Yes | |||||
Profile for product number 004
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SUPPOSITORY;VAGINAL | Strength | 1.05GM | ||||
| Approval Date: | Jan 27, 1987 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
